MLLT3 and leukemia: EED directly interacts with EZH2, therefore Orkin and colleagues developed peptides that selectively disrupt the EED/EZH2 interaction, thereby reducing EZH2 protein levels as well as H3K27me3 in MLL-AF9-mediated leukemia (Kim et al., 2013).